IntelGenx Technologies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Dwight Gorham

Chief executive officer

US$819.6k

Total compensation

CEO salary percentage	20.2%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	2.5yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dwight Gorham's remuneration changed compared to IntelGenx Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$820k	US$165k	-US$10m

Compensation vs Market: Dwight's total compensation ($USD819.56K) is about average for companies of similar size in the US market ($USD689.66K).

Compensation vs Earnings: Insufficient data to compare Dwight's compensation with company performance.

CEO

Dwight Gorham (66 yo)

1.3yrs

Tenure

US$819,564

Compensation

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also serves as its Director since May 2024 and also Joined the company on April 13, 2023. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dwight Gorham	CEO & Director	1.3yrs	US$819.56k	no data
André Godin	President & CFO	9yrs	US$422.32k	0.44% $ 129.2k
Tommy Kenny	Senior VP & General Counsel	3.6yrs	US$176.92k	0.13% $ 37.0k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% $ 27.1k
Karen Kalayajian	Vice President of Finance & Administration	1.3yrs	no data	0.16% $ 47.0k
Stephen Kilmer	Investor Relations Officer	no data	no data	no data
Ingrid Zerbe	Corporate Secretary	18.3yrs	no data	0.053% $ 15.6k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	no data	no data

2.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: IGXT's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dwight Gorham	CEO & Director	less than a year	US$819.56k	no data
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.5yrs	US$163.33k	0.093% $ 27.1k
Mark Nawacki	Independent Vice Chairman	8yrs	US$83.59k	0% $ 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.3yrs	US$216.39k	0.0026% $ 758.4
Serge Gauthier	Member of Scientific Advisory Board	no data	no data	no data
Bernd Melchers	Independent Director	15.3yrs	US$83.59k	0.069% $ 20.0k
Barry Greenberg	Member of Scientific Advisory Board	8.5yrs	no data	no data
Ludwig Aigner	Member of Scientific Advisory Board	8.5yrs	no data	no data
Monika Trzcinska	Independent Director	2.3yrs	US$75.57k	no data

8.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: IGXT's board of directors are considered experienced (8.5 years average tenure).

IntelGenx Technologies Management

Management criteria checks 3/4

Key information

Recent management updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. Announces Board Resignations

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

Recent updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. announced delayed 10-Q filing

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

IntelGenx Technologies Corp. Announces Board Resignations

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age